Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Tiziana Life Sciences

Next Previous
Drug Profile

Research programme: cancer therapeutics - Tiziana Life Sciences

Alternative Names: Anti-cancer stem cell agent - Tiziana; Bcl3i molocules - Cardiff University/ Tiziania Life Sciences; CB1; cFLIP inhibitors; JS6; OH 14; TZLS 214; TZLS101

Latest Information Update: 21 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiff University
  • Developer Cardiff University; Tiziana Life Sciences
  • Class Small molecules
  • Mechanism of Action Apoprotein stimulants; Bcl-X protein inhibitors; Molecular motor protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 21 Aug 2024 Discontinued - Preclinical for Breast cancer (Late-stage disease) in United Kingdom (unspecified route) (Tiziana Life Sciences pipeline, August 2024)
  • 21 Aug 2024 Discontinued - Preclinical for Colorectal cancer (Late-stage disease) in United Kingdom (unspecified route) (Tiziana Life Sciences pipeline, August 2024)
  • 28 Jul 2020 No recent reports of development identified for preclinical development in Colorectal-cancer(Late-stage disease) in United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top